New drug duo aims to control aggressive blood cancers
NCT ID NCT00392353
Summary
This study is testing the safety and effectiveness of combining two drugs, vorinostat and azacitidine, for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination can better control the disease by stopping the growth of abnormal blood cells. The trial enrolled 135 patients and is no longer recruiting new participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
North Shore University Hospital
Manhasset, New York, 11030, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.